Abstract
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19– relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma
Cell Death & Disease Open Access 16 October 2022
-
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Nature Communications Open Access 11 June 2022
-
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
Signal Transduction and Targeted Therapy Open Access 04 April 2022
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Grupp, S. A. et al. Blood 122, 67 (2013).
Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).
Maude, S. L. et al. Blood 128, 2801 (2016).
Buechner, J. et al. EHA 17, abstr. S476 (2017).
Wang, Z., Wu, Z., Liu, Y. & Han, W. J. Hematol. Oncol. 10, 53 (2017).
Ruella, M. & Maus, M. V. Comput. Struct. Biotechnol. J. 14, 357–362 (2016).
Riester, M. et al. Source Code Biol. Med. 11, 13 (2016).
Sotillo, E. et al. Cancer Discov. 5, 1282–1295 (2015).
Shen, S. et al. Proc. Natl. Acad. Sci. USA 111, E5593–E5601 (2014).
Jacoby, E. et al. Nat. Commun. 7, 12320 (2016).
Gardner, R. et al. Blood 127, 2406–2410 (2016).
Sommermeyer, D. et al. Leukemia 31, 2191–2199 (2017).
Shah, N. N. et al. Blood 128, 650 (2016).
Topp, M. S. et al. J. Clin. Oncol. 32, 4134–4140 (2014).
Zugmaier, G. et al. Blood 126, 2578–2584 (2015).
Cibulskis, K. et al. Nat. Biotechnol. 31, 213–219 (2013).
Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Bioinformatics 25, 2865–2871 (2009).
Sherry, S. T. et al. Nucleic Acids Res. 29, 308–311 (2001).
Forbes, S. A. et al. Nucleic Acids Res. 43, D805–D811 (2015).
Li, H. & Durbin, R. Bioinformatics 25, 1754–1760 (2009).
McKenna, A. et al. Genome Res. 20, 1297–1303 (2010).
DePristo, M. A. et al. Nat. Genet. 43, 491–498 (2011).
Acknowledgements
The authors thank the patients and their families for participating in these clinical trials and A. Abrams for figure design.
Author information
Authors and Affiliations
Contributions
J.E.L., M.Q., S.A.G., M.B., B.D.M., E.R.N., H. Bittencourt, H.H., J.B., S.M.D., and M.V. contributed patient samples for sequencing. P.A.W. provided clinical data on the patients. R.J.L. oversaw the DNA- and RNA-seq. E.J.O. and M.R. analyzed and interpreted the sequencing data. X.H., P.P., and K.N. analyzed and interpreted the flow cytometry MRD assay data. W.W., J.A.E., H. Bitter, M.M., J.L.B., C.T., and S.P. provided guidance and scientific input. E.J.O. wrote the paper, with contributions from all authors.
Corresponding author
Ethics declarations
Competing interests
The research samples used in this manuscript come from patients treated on clinical trials conducted by Novartis. J.E.L., M.Q., H. Bittencourt, S.M.D, and S.A.G. consult for Novartis. E.J.O., X.H., C.T., P.A.W., R.J.L., M.R., J.L.B., H.Bitter, M.M., P.P., S.P., J.A.E., and W.W. are employed by Novartis or were employed by Novartis at the time of manuscript preparation.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–4 and Supplementary Tables 1–6
Supplementary Data Table
Supplementary Data Table 1
Rights and permissions
About this article
Cite this article
Orlando, E.J., Han, X., Tribouley, C. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 24, 1504–1506 (2018). https://doi.org/10.1038/s41591-018-0146-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0146-z
This article is cited by
-
Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis
Annals of Hematology (2023)
-
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
Leukemia (2023)
-
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
Experimental Hematology & Oncology (2022)
-
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Nature Communications (2022)
-
Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma
Cell Death & Disease (2022)
